ly3202626
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02323334)
Timeline
Indications
Mechanism of action
- Beta-secretase 1INHIBITOR
BACE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3202626
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03023826 | Phase 1 | Jan 15, 2017 | Eli Lilly |
| NCT02791191 | Phase 2 | Jun 1, 2016 | Eli Lilly |
| NCT02555449 | Phase 1 | Sep 1, 2015 | Eli Lilly |
| NCT02323334 | Phase 1 | Dec 1, 2014 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 2 | 2014 |
1 organizations
Page 1 / 1